TY - JOUR
T1 - Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: A study from the Lunenburg Lymphoma Biomarker Consortium
AU - Salles, Gilles
AU - De Jong, Daphne
AU - Xie, Wanling
AU - Rosenwald, Andreas
AU - Chhanabhai, Mukesh
AU - Gaulard, Philippe
AU - Klapper, Wolfram
AU - Calaminici, Maria
AU - Sander, Birgitta
AU - Thorns, Christoph
AU - Campo, Elias
AU - Molina, Thierry
AU - Lee, Abigail
AU - Pfreundschuh, Michael
AU - Horning, Sandra
AU - Lister, Andrew
AU - Sehn, Laurie H.
AU - Raemaekers, John
AU - Hagenbeek, Anton
AU - Gascoyne, Randy D.
AU - Weller, Edie
PY - 2011/6/30
Y1 - 2011/6/30
N2 - The Lunenburg Lymphoma Biomarker Consortium (LLBC) evaluated the prognostic value of IHC biomarkers in a large series of patients with diffuse large B-cell lymphoma (DLBCL). Clinical data and tumor samples were retrieved from 12 studies from Europe and North America, with patients treated before or after the rituximab era. Using tissue microarrays from 1514 patients, IHC for BCL2, BCL6, CD5, CD10, MUM1, Ki67, and HLA-DR was performed and scored according to previously validated protocols. Optimal cut points predicting overall survival of patients treated in the rituximab era could only be determined for CD5 (P = .003) and Ki67 (P = .02), whereas such cut points for BCL2, BCL6, HLA-DR, and MUM1 could only be defined in patients not receiving rituximab. A prognostic model for patients treated in the rituximab era identified 4 risk groups using BCL2, Ki67, and International Prognostic Index (IPI) with improved discrimination of low-risk patients. Newly recognized correlations between specific biomarkers and IPI highlight the importance of carefully controlling for clinical and biologic factors in prognostic models. These data demonstrate that the IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy.
AB - The Lunenburg Lymphoma Biomarker Consortium (LLBC) evaluated the prognostic value of IHC biomarkers in a large series of patients with diffuse large B-cell lymphoma (DLBCL). Clinical data and tumor samples were retrieved from 12 studies from Europe and North America, with patients treated before or after the rituximab era. Using tissue microarrays from 1514 patients, IHC for BCL2, BCL6, CD5, CD10, MUM1, Ki67, and HLA-DR was performed and scored according to previously validated protocols. Optimal cut points predicting overall survival of patients treated in the rituximab era could only be determined for CD5 (P = .003) and Ki67 (P = .02), whereas such cut points for BCL2, BCL6, HLA-DR, and MUM1 could only be defined in patients not receiving rituximab. A prognostic model for patients treated in the rituximab era identified 4 risk groups using BCL2, Ki67, and International Prognostic Index (IPI) with improved discrimination of low-risk patients. Newly recognized correlations between specific biomarkers and IPI highlight the importance of carefully controlling for clinical and biologic factors in prognostic models. These data demonstrate that the IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=79959852471&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-04-345256
DO - 10.1182/blood-2011-04-345256
M3 - Journal articles
C2 - 21536860
AN - SCOPUS:79959852471
SN - 0006-4971
VL - 117
SP - 7070
EP - 7078
JO - Blood
JF - Blood
IS - 26
ER -
